News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hutchison China MediTech (Chi-Med): Director's Share Dealing



11/2/2016 11:31:11 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

HONG KONG, CHINA--(Marketwired - November 01, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)

Director's Share Dealing

London: Tuesday, November 1, 2016: Hutchison China MediTech Limited ("Chi-Med") (NASDAQ: HCM) (AIM: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at an average price of GBP18.453305 per share between October 24, 2016 and October 28, 2016 under a personal share trading plan (the "Plan"). Pursuant to the Plan, a total of 20,000 Ordinary Shares will be sold between October 24, 2016 and November 23, 2016 (inclusive). The Plan (and the previous sale of 15,000 Ordinary Shares made by Mr Howell on October 7, 2016) has been put in place to facilitate financial settlement arising from a marital separation agreement.

Following the above sale of 10,000 Ordinary Shares, the holding of Mr Howell is 128,600 Ordinary Shares, representing approximately 0.21% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities/person closely associated a) Name Mr Michael Howell 2 Reason for the notification a) Position/status Independent Non-executive Director of Chi- Med b) Initial Initial notification notification/Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hutchison China MediTech Limited b) LEI N/A 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial Ordinary Shares of US$1.00 each instrument, type of DI ISIN: KYG4672N1016 instrument ADS ISIN: US44842L1035 Identification code b) Nature of the transaction Sale of 10,000 Ordinary Shares between October 24, 2016 and October 28, 2016 at an average price of GBP18.453305 Price(s) Volume(s) GBP18.25 339 GBP18.30 2,661 GBP18.40 1,000 GBP18.50 3,500 GBP18.60 2,500 d) Aggregated information Aggregated volume: 10,000 Price information: GBP18.453305 - Aggregated volume - Price e) Date of the transaction 2016-10-24; 14:07 - disposal of 339 Ordinary Shares 2016-10-25; 14:05 - disposal of 661 Ordinary Shares 2016-10-25; 14:44 - disposal of 2,000 Ordinary Shares 2016-10-25; 15:29 - disposal of 1,000 Ordinary Shares 2016-10-26; 13:57 - disposal of 3,000 Ordinary Shares 2016-10-28; 12:48 - disposal of 2,500 Ordinary Shares 2016-10-28; 14:09 - disposal of 500 Ordinary Shares f) Place of the transaction London Stock Exchange (XLON)

NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

Investor Enquiries Christian Hogg, CEO +852 2121 8200 International Media Enquiries Anthony Carlisle, +44 7973 611 888 anthony.carlisle@cdrconsultancy.co.uk Citigate Dewe (Mobile) Rogerson U.S. Based Media Enquiries Brad Miles, BMC +1 (917) 570 7340 bmiles@bmccommunications.com Communications (Mobile) Susan Duffy, BMC +1 (917) 499 8887 sduffy@bmccommunications.com Communications (Mobile) Investor Relations Matt Beck, The Trout +1 (917) 415 1750 mbeck@troutgroup.com Group (Mobile) David Dible, +44 7967 566 919 david.dible@citigatedr.co.uk Citigate Dewe (Mobile) Rogerson Panmure Gordon (UK) Limited Richard Gray / +44 (20) 7886 2500 Andrew Potts


Contacts:
RNS
Customer Services
0044-207797-4400
rns@londonstockexchange.com
http://www.rns.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES